No profile data available.
MacroGenics, Inc. (MGNX) is a healthcare company in the additional cancer treatment drugs industry, based in Rockville, United States, with about 293 full-time employees.
It reported revenue of $149.50 million for fiscal year 2025, up 0.8% from fiscal year 2024, and net income of -$74.62 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $32.83 million, up 47.6% from a year before. Its market capitalization was $238.24 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States.
MacroGenics reported $149.50 million in revenue for fiscal year 2025, up 0.8% from $148.34 million in fiscal year 2024. In Q2 2026 revenue was $32.83 million.
$238.24 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Zentalis Pharmaceuticals, Inc. (ZNTL), Immuneering Corporation (IMRX), Pyxis Oncology, Inc. (PYXS), Sutro Biopharma, Inc. (STRO).